相似文献
1
Targeting DNA topoisomerase II in cancer chemotherapy.
Nat Rev Cancer. 2009 May;9(5):338-50. doi: 10.1038/nrc2607. Epub 2009 Apr 20.
2
Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
Biochem J. 1997 May 15;324 ( Pt 1)(Pt 1):329-39. doi: 10.1042/bj3240329.
3
[Molecular determinants of response to topoisomerase II inhibitors].
Bull Cancer. 2011 Nov;98(11):1299-310. doi: 10.1684/bdc.2011.1475.
4
Single-molecule Förster resonance energy transfer (FRET) analysis discloses the dynamics of the DNA-topoisomerase II (Top2) interaction in the presence of TOP2-targeting agents.
J Biol Chem. 2017 Jul 28;292(30):12589-12598. doi: 10.1074/jbc.M117.792861. Epub 2017 Jun 19.
5
Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An Approach.
Curr Cancer Drug Targets. 2017;17(7):657-668. doi: 10.2174/1568009617666161109142629.
6
NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
J Biol Chem. 2008 Aug 29;283(35):23711-20. doi: 10.1074/jbc.M803936200. Epub 2008 Jul 2.
7
Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
Mol Pharmacol. 2022 Jan;101(1):24-32. doi: 10.1124/molpharm.121.000374. Epub 2021 Oct 23.
8
DNA topoisomerase II and its growing repertoire of biological functions.
Nat Rev Cancer. 2009 May;9(5):327-37. doi: 10.1038/nrc2608. Epub 2009 Apr 20.
9
Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Elife. 2020 Feb 14;9:e53447. doi: 10.7554/eLife.53447.
10
Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Mol Biol Rep. 2021 Sep;48(9):6589-6601. doi: 10.1007/s11033-021-06665-7. Epub 2021 Sep 2.
引用本文的文献
1
Exploring the anticancer and antioxidant properties of Lagerstroemia speciosa bark extract via phytochemical and molecular docking analysis.
J Genet Eng Biotechnol. 2025 Sep;23(3):100553. doi: 10.1016/j.jgeb.2025.100553. Epub 2025 Aug 14.
2
Naphthalimide-organometallic hybrids as multi-targeted anticancer and luminescent cellular imaging agents.
RSC Med Chem. 2025 Aug 8. doi: 10.1039/d5md00205b.
3
Integrative single-cell and bulk transcriptomic analyses identify a robust four-gene signature for risk stratification in neuroblastoma.
Transl Cancer Res. 2025 Jul 30;14(7):3920-3929. doi: 10.21037/tcr-2025-569. Epub 2025 Jul 4.
4
Distinct In Vitro Effects of Liposomal and Nanostructured Lipid Nanoformulations with Entrapped Acidic and Neutral Doxorubicin on B16-F10 Melanoma and Walker 256 Carcinoma Cells.
Pharmaceutics. 2025 Jul 12;17(7):904. doi: 10.3390/pharmaceutics17070904.
5
Inhibition of UBE2C Promotes Parkin-Mediated K63-Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer.
Adv Sci (Weinh). 2025 Aug;12(32):e17348. doi: 10.1002/advs.202417348. Epub 2025 Jul 29.
6
Potent β-lactam-based tyrosyl-DNA phosphodiesterase 1 inhibitors identified by a virtual screen.
Sci Rep. 2025 Jul 21;15(1):26510. doi: 10.1038/s41598-025-12503-8.
7
Dynamic crosstalk between amino acid metabolism and cancer drug efficacy: From mechanisms to therapeutic opportunities.
iScience. 2025 Apr 11;28(5):112405. doi: 10.1016/j.isci.2025.112405. eCollection 2025 May 16.
8
The protective effect of curcumin nanoparticles on renal damage caused by a combination of bleomycin, etoposide, and cisplatin.
BMC Nephrol. 2025 Jul 5;26(1):354. doi: 10.1186/s12882-025-04286-x.
9
ATP-competitive inhibitors for cancer treatment - kinases and the world beyond.
RSC Med Chem. 2025 Jun 25. doi: 10.1039/d5md00235d.
10
DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses.
Sci Rep. 2025 Jul 2;15(1):23330. doi: 10.1038/s41598-025-06705-3.
本文引用的文献
1
Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.
Mol Cell. 2009 Jan 16;33(1):117-23. doi: 10.1016/j.molcel.2008.11.021.
2
Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.
BMC Chem Biol. 2009 Jan 7;9:1. doi: 10.1186/1472-6769-9-1.
3
Topoisomerase IIalpha controls the decatenation checkpoint.
Nat Cell Biol. 2009 Feb;11(2):204-10. doi: 10.1038/ncb1828. Epub 2008 Dec 21.
4
Recent advances in protection against doxorubicin-induced toxicity.
Technol Cancer Res Treat. 2008 Dec;7(6):497-516. doi: 10.1177/153303460800700611.
5
The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Biochemistry. 2008 Nov 11;47(45):11900-8. doi: 10.1021/bi800981j. Epub 2008 Oct 16.
6
Anthracycline-induced cardiotoxicity.
Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):278-81. doi: 10.2174/187152508785909474.
7
Bortezomib as a therapeutic candidate for neuroblastoma.
J Exp Ther Oncol. 2008;7(2):135-45.
8
Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.
J Biol Chem. 2008 Oct 24;283(43):29239-50. doi: 10.1074/jbc.M804058200. Epub 2008 Aug 22.
9
Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide.
Int J Oncol. 2008 Sep;33(3):613-21.
10
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Invest New Drugs. 2009 Feb;27(1):53-62. doi: 10.1007/s10637-008-9154-z. Epub 2008 Jul 11.
Zotero 插件